What question did this study set out to answer?

This research aims to identify factors that predict left ventricular systolic dysfunction in patients treated with mavacamten for obstructive hypertrophic cardiomyopathy.

January 10, 2026Journal of Cardiac Failure - Intersections0 citationsOpen Access

Predictors of Left Ventricular Systolic Dysfunction during Treatment with Mavacamten for Obstructive Hypertrophic Cardiomyopathy

DMDaniele MasseraGeneral Cardiology EAElizabeth Adlestein YLYi LiCentral South University of Forestry and Technology

Key Points

This research aims to identify factors that predict left ventricular systolic dysfunction in patients treated with mavacamten for obstructive hypertrophic cardiomyopathy.
Analyzed clinical data from patients undergoing treatment with mavacamten.

Structured PICO

Population

Symptomatic adults with obstructive hypertrophic cardiomyopathy (oHCM), left ventricular outflow tract (LVOT) gradients of ≥30 mmHg at rest or ≥50 mmHg with provocation refractory to first-line therapy, and NYHA class ≥2 symptoms enrolled in a single-center HCM program registry.

Intervention

Mavacamten for ≥8 weeks

Outcome

Predictors of left ventricular systolic dysfunction (LVSD)safety

Abstract

The cardiac myosin inhibitor mavacamten is used to alleviate symptoms in obstructive hypertrophic cardiomyopathy (oHCM).1, 2 However, it can cause left ventricular systolic dysfunction (LVSD), which occurred in 8.7% of patients in EXPLORER-HCM and 13.8% in VALOR-HCM,3, 4 and less frequently in clinical cohorts.5 Given differences in baseline demographics, we hypothesized that certain features would be associated with LVSD. Accordingly, we examined predictors of LVSD in a single-center cohort of symptomatic adults with oHCM, left ventricular outflow tract (LVOT) gradients of ≥30 mmHg at rest or ≥50 mmHg with provocation refractory to first-line therapy, NYHA class ≥2 symptoms treated with mavacamten for ≥8 weeks who enrolled in the HCM program registry All patients signed informed consent as approved by the NYU Grossman School of Medicine institutional review board.

Ask AI

Helpful

Bookmark

View Full Paper